What is Gaucher disease and how is it inherited?

Gaucher disease is a lysosomal storage disorder caused by mutations in the GBA gene, which encodes the enzyme glucocerebrosidase. Without it, glucocerebroside accumulates in macrophages in the spleen, liver, and bone marrow. Gaucher is autosomal recessive — both GBA copies must be defective. The N370S mutation is particularly common in Ashkenazi Jewish people (1 in 14–15 are carriers).

What are the three types of Gaucher disease?

Type 1 (non-neuronopathic) — ~95% of cases; no brain involvement; splenomegaly, hepatomegaly, bone disease, anemia; highly treatable. Type 2 (acute neuronopathic) — rare; severe brain involvement in infancy; typically fatal by age 2–3. Type 3 (subacute neuronopathic) — rare; variable neurological progression with systemic features.

Is Gaucher disease linked to Parkinson's disease?

Yes — heterozygous GBA mutations (carriers) have a 5–10× higher risk of developing Parkinson's disease. GBA is now the most common genetic risk factor for Parkinson's. All Gaucher patients and their families should be aware of this risk and consider neurological monitoring.

How much does Gaucher treatment cost?

ERT (Cerezyme, VPRIV) typically costs $200,000–$400,000/year. Oral SRT (Cerdelga) runs ~$220,000/year. However, all manufacturers have extensive patient assistance programs. The National Gaucher Foundation (gaucherdisease.org) helps navigate financial assistance.

🧬

Gaucher Disease

Gaucher disease is the most common lysosomal storage disorder — a genetic condition where the body cannot properly break down a fatty substance called glucocerebroside. It accumulates in organs, particularly the spleen, liver, and bone marrow, causing organ enlargement, anemia, bone pain, and fractures. Enzyme replacement therapy (ERT) has transformed outcomes — patients on treatment can live normal lives.

📊 Gaucher disease affects approximately 1 in 40,000 people in the general population — but 1 in 800 among Ashkenazi Jewish individuals. Approximately 6,000–10,000 Americans live with Gaucher disease.

Gaucher disease Gaucher lysosomal storage disorder glucocerebrosidase Cerezyme VPRIV

Get Free Updates → View Treatments Join Debate ⚡

👥 ~10,000 in US · Patients in US

🏥 Metabolic / Genetics · Specialty

💊 4 available · FDA-approved drugs

FDA-Approved Treatments

Current approved therapies — what they are, who makes them, and what to ask your doctor.

Cerezyme

imiglucerase · Sanofi

Enzyme Replacement Therapy (IV)

The original and most widely prescribed ERT for Gaucher Type 1. Imiglucerase is a recombinant form of glucocerebrosidase — the enzyme Gaucher patients lack. Given as a biweekly IV infusion. Has been used since 1994 and has an extensive safety record.

💰 ~$200,000–$400,000/year IV infusion every 2 weeks ✓ Patient Assist

VPRIV

velaglucerase alfa · Takeda

Enzyme Replacement Therapy (IV)

Second-generation ERT approved 2010. Human cell-line derived — potentially lower immunogenicity. Non-inferior to imiglucerase in clinical trials.

💰 ~$200,000–$350,000/year IV infusion every 2 weeks ✓ Patient Assist

Cerdelga

eliglustat · Sanofi

Substrate Reduction Therapy (oral)

First oral treatment approved for Gaucher Type 1 (2014). Substrate reduction therapy — reduces production of the substrate that accumulates. Requires CYP2D6 genotyping. Non-inferior to Cerezyme in ENGAGE trial. Major quality-of-life advantage: no IV infusions.

💰 ~$220,000/year Oral twice daily ✓ Patient Assist

Zavesca

miglustat · Actelion (J&J)

Substrate Reduction Therapy (oral)

Oral SRT approved 2003 for patients for whom ERT is unsuitable. Crosses the blood-brain barrier — used for neurological complications in Type 3 Gaucher. More GI side effects than Cerdelga.

💰 ~$150,000/year Oral three times daily ✓ Patient Assist

Community Feed

What patients and caregivers are saying about Gaucher

View All →

Have something to share?

Join the Gaucher community discussion on /pulse — share your experience, ask questions, or post research you've found.

Go to Pulse →

CiteYourSource Arena ⚡

Fact-checked debates about Gaucher — cite your source, AI scores your claim

Debate Now →

Make a claim about Gaucher

Back it up with sources. Our AI scores your claim for factual accuracy — 0 to 100. Top scorers appear on the leaderboard.

Enter the Arena →

📋 Newly Diagnosed Guide

Newly diagnosed with Gaucher disease? Here's what to do first.

🧬

1. See a metabolic/genetics specialist with Gaucher experience

Gaucher disease is rare enough that most internists have limited experience. Find a physician at a center with a dedicated lysosomal storage disorder program. The National Gaucher Foundation (gaucherdisease.org) maintains a specialist directory.

🩺

2. Get a complete baseline workup before starting treatment

Standard baseline: CBC, liver function tests, spleen/liver volume by MRI, DEXA bone density, chitotriosidase and lyso-GL1 levels, and GBA genotyping. These establish disease severity and track treatment response.

💊

3. Treatment decision: ERT vs oral SRT

For Type 1 Gaucher, both IV ERT (Cerezyme/VPRIV) and oral SRT (Cerdelga) are effective first-line options. Cerdelga requires CYP2D6 genotyping and eliminates biweekly infusions. Work with your specialist to choose based on your genotype and lifestyle.

🫳

4. Monitor for Parkinson's risk in yourself and family

GBA mutations significantly increase Parkinson's risk — even in carriers. Alert first-degree relatives to get genetic counseling, especially if anyone in the family has Parkinson's or tremors.

🔔 FREE ALERTS + PERSONALIZED UPDATES

Get Gaucher Research Updates — Personalized to Your Situation

Weekly updates from NIH, FDA, and ClinicalTrials.gov. Tell us about your situation and we'll filter what's most relevant for you. Free. No spam.

Only email is required. By subscribing you agree to receive updates from My Sugar Pill. We never sell your data. Privacy policy.

Frequently Asked Questions

Real questions from patients and caregivers — answered in plain English.